OCV C02

Drug Profile

OCV C02

Alternative Names: OCV-103/104; OCV-103/OCV-104; OCV-104/103; OCV-104/OCV-103; OCV-C02; OTS 103/104

Latest Information Update: 23 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator OncoTherapy Science
  • Developer OncoTherapy Science; Otsuka Pharmaceutical
  • Class Cancer vaccines; Immunotherapies; Peptide vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Colorectal cancer

Most Recent Events

  • 20 Nov 2017 OCV C02 is still in phase I trials for Colorectal cancer (Late-stage disease, Second-line therapy or greater) in Japan (Parenteral, Injection) (Otsuka Pharmaceutical pipeline, November 2017)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Colorectal-cancer(Late-stage disease, Second-line therapy or greater) in Japan (Parenteral, Injection)
  • 18 Jan 2017 Efficacy, safety and immunological data from a phase I trial in Colorectal cancer released by Otsuka Pharmaceutical
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top